Physician profile
Rajesh Patel
NPI 1144214925
$12,736.34
in general payments reported to CMS, 2019-2025
31 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $1,327 · 2021: $1,675 · 2022: $1,996 · 2023: $1,669 · 2024: $1,914 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,278 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.90 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,127.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,926.07 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,463.85 | 2019-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $1,393.54 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $925.83 | 2019-2024 | Yupelri, Yupelri |
| Genzyme Corporation | $836.86 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $476.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $322.09 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $282.87 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $256.80 | 2019 | |
| Genentech USA, INC. | $237.02 | 2019-2021 | |
| Amgen INC. | $200.71 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $197.75 | 2019-2024 | Tyvaso |
| Insmed, INC. | $180.98 | 2019-2025 | Brinsupri, Arikayce |
| Viatris Specialty LLC | $156.34 | 2025 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $126.03 | 2024-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $110.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $100.66 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $85.78 | 2021-2022 | |
| Verona Pharma, INC. | $74.60 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $63.94 | 2019-2024 | Zerbaxa |
| Ambu INC. | $30.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $29.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.54 | 2021 | |
| La Jolla Pharmaceutical Company | $21.91 | 2024 | Giapreza |
| Inspire Medical Systems, INC. | $18.17 | 2023 | Inspire |
| Nabriva Therapeutics, Plc | $15.54 | 2021 | |
| Pulmonx Corporation | $13.08 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Circassia INC. | $12.50 | 2020 | |
| Pfizer INC. | $12.46 | 2019 | |
| Vapotherm INC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.